NCT06291038

Efficacy of Glutamine Supplementation in Patients Suffering From Irritable Bowel Syndrome With Impaired Intestinal Permeability

Name: Clinical Trial NCT06291038
Creator: University Hospital, Rouen
Keywords: Irritable Bowel Syndrome, • Experimental group: treatment with glutamine at a dose of 5g 3 times a day for 8 weeks, dietary supplement, clinical trial

Efficacy of Glutamine Supplementation in Patients Suffering From Irritable Bowel

University Hospital, Rouen·ClinicalTrials.gov·dietary supplementNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Irritable Bowel Syndrome
Drug/Device/Intervention: • Experimental group: treatment with glutamine at a dose of 5g 3 times a day for 8 weeks
Study type: Interventional
Intervention type: dietary supplement

Sponsor & location

Primary sponsor: University Hospital, Rouen

Timeline & enrollment

Phase: N/A
Start date: Jul 01, 2024
End date: Mar 01, 2029
Enrollment: 60 participants

Primary outcome

Evaluate the symptomatic effectiveness of glutamine supplementation in patients suffering from IBS-D with increased intestinal permeability

Summary

Irritable bowel syndrome (IBS) affects approximately 5% of the general population and remains a daily problem in the practice of clinicians with inconsistent effectiveness of treatments while patients' expectations are high.  One of the functional abnormalities described during IBS is increased intestinal permeability. This increase in intestinal permeability is primarily present in the diarrheal subtype (IBS-D) and can be measured using the lactulose/mannitol test.  Glutamine is a non-essential amino acid which regulates numerous metabolic pathways, and which plays a key role in the intestine because it is the preferential substrate of enterocytes and immune cells. Ex vivo, glutamine is able to restore the expression of tight junction proteins in patients suffering from IBS-D. On the other hand, glutamine supplementation is capable of reducing abdominal pain and restoring intestinal permeability disorders in a subgroup of patients with intestinal permeability disorder (post-infectious IBS-D).  Our working hypothesis would be that all patients suffering from IBS with permeability disorder, measured by the lactulose/mannitol test, could benefit from oral glutamine supplementation.

ICD-10 classifications

Irritable bowel syndromeOther and unspecified irritable bowel syndromeIrritable bowel syndrome with mixed bowel habits [IBS-M]Irritable bowel syndrome with predominant constipation [IBS-C]Irritable bowel syndrome with predominant diarrhoea [IBS-D]

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06291038
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06291038 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital, Rouen and is currently Not yet recruiting. The study focuses on Irritable Bowel Syndrome. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.